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Abstract 
Background:  Awareness of a patient’s anxiety, depression, and quality of life (QOL) in those 
with metastatic uveal melanoma (MUM) can influence care that meets patients’ bio-psycho-
social-spiritual needs. 
Objectives: To measure the level of anxiety, depression, and QOL in patients with MUM and 
explore differences by gender, age range, time to metastatic disease, and duration of illness since 
metastasis. 
Methods: We used a descriptive-comparative survey design. Over three months, a convenience 
sample of 70 patients with MUM aged ≥ 18 years, treated at a Mid-Atlantic hospital were invited 
to complete a combined survey of the Hospital Anxiety and Depression Scale and the World 
Health Organization Quality of Life-BREF.  
Results: There were 65 respondents (93% response rate). 30.8% (n=20) had at least borderline 
anxiety, 13.8% (n=9) had at least borderline depression, and 32.3% (n=21) had a decrease in 
global QOL. Patients 18 to ≤ 60 years had higher anxiety scores (p=0.003) and lower QOL 
scores in environmental health (p=0.006). Those with a shorter duration of illness since 
metastasis had higher anxiety scores (p=0.01) and higher QOL scores in physical health 
(p=0.05). No differences were found by gender or time to metastatic disease. 
Conclusions: Up to 30% of participants had at least borderline anxiety and a decreased global 
QOL while up to 10% had at least borderline depression. These findings support the integration 
of bio-psycho-social-spiritual practices in the care of patients with MUM. 
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Background 
The comprehensive health care approach encompasses services that are pertinent to the 
well-being of individuals. It utilizes integrated interprofessional teams to address physical, 
social, and psychological needs of patients throughout the continuum of care (Bakitas, Lyons, 
Hegel, & Ahles, 2013). Yet, challenges remain in addressing psychosocial needs of patients, 
especially those who are faced with life threatening illnesses. One particularly vulnerable group 
is that of patients diagnosed with metastatic uveal melanoma (MUM), a rare and incurable 
malignancy that originates as a melanoma of the uveal tract without known risk factors 
(American Cancer Society [ACS], 2014).  
Epidemiology of Metastatic Uveal Melanoma  
This tumor is prevalent among people of northern European descent with blue eyes, fair 
skin, and those with outdoor occupations (Eschelman, Gonsalves, & Sato, 2013). However, 
unlike skin melanoma, there is no convincing evidence that uveal melanoma is related to 
ultraviolet exposure (Eschelman et al., 2013). In the United States, approximately 2,000 adults 
are diagnosed with ocular melanoma annually (Ocular Melanoma Foundation, 2016). The 
prognosis of uveal melanoma remains poor with a 5-year relative survival rate of 75% if cancer 
is confined to the uveal tract compared to only 15% in case of metastasis despite advanced 
treatment technologies (ACS, 2014).  
Treatment of Metastatic Uveal Melanoma  
The most common treatment of primary uveal melanoma includes eye radiation for small 
tumors and eye enucleation for complicated tumors (Eschelman et al., 2013; Shields & Shields, 
2004). Despite intraocular melanoma therapy, about 50% of patients with primary uveal 
melanoma develop distant metastasis, the liver is affected in about 90%, lung in 29%, and bone 
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in 17% (Buder, Gesierich, Goebeler, & Gelbrich, 2013; Eschelman, et al., 2013; Spagnolo, 
Caltabiano, & Queirolo, 2012). When hepatic metastasis occurs, locoregional therapy to the liver 
is recommended to stabilize tumor growth and halt the progression of disease (Eschelman et al., 
2013). Systemic treatment approaches are suggested when extrahepatic metastasis occurs.  
The treatment of metastatic uveal melanoma is complex and requires highly specialized 
care in referral practices of MUM. A large teaching hospital in the Mid-Atlantic offers 5 leading 
modalities of liver directed treatment for MUM, namely immunoembolization, selective internal 
radiation therapy, transarterial chemoembolization, drug-eluting beads (Eschelman et al., 2013), 
and chemosaturation with percutaneous hepatic perfusion. Also, this referral practice of MUM is 
one of the few institutions worldwide that offer a systemic clinical trial of immunocore gp100, an 
orphan drug targeting T-cell receptors for the treatment of MUM (Immunocore Limited, 2016). 
Every week, about 15 patients with MUM come to this hospital seeking liver directed therapy or 
systemic immunotherapies. In 2016, approximately 640 liver-directed treatment procedures were 
performed for patients with MUM in this institution. While the medical treatment of these 
patients continues to evolve with new technologies, identification and treatment of co-morbid 
anxiety, depression, and other psychosocial problems needs attention.  
Problem Statement 
Patients diagnosed with MUM undergo multiple tests and treatments from the initial 
diagnosis of uveal melanoma to metastasis. These events may lead to psychological distress and 
life-changing challenges, which should require unique assessment and intervention throughout 
the continuum of care, survivorship, and end of life. In this organization, psychosocial needs of 
patients with MUM have not been routinely assessed and addressed in everyday clinical practice. 
Yet, if you are caring for the whole patient, these issues need to be incorporated in providing 
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holistic care (Dossey & Keegan, 2013). Hence, identifying and isolating these psychosocial 
needs could lead to the development and implementation of strategies that put forward 
psychosocial care in an attempt to ameliorate the quality of life of these patients (Dossey & 
Keegan, 2013). Considering the number of patients with MUM who seek care within this 
organization, we believed that investigation of their psychosocial health status was warranted. 
Purpose 
The purpose of this study was to assess the levels of anxiety, depression, and quality of 
life of patients with MUM. The long term purpose of this research is to design an 
interprofessional translational action plan geared toward addressing bio-psycho-social-spiritual 
needs and ultimately, improving quality of life and holistic well-being of patients with MUM. 
Objectives 
The primary objective of this pilot study was to measure the level of anxiety, depression, 
and quality of life in patients with MUM. The secondary objective was to explore potential 
differences in the levels of anxiety, depression, and quality of life by gender, age range, time 
elapsed between the initial diagnosis of uveal melanoma and metastasis, and duration of illness 
since the diagnosis of metastasis. 
Research Questions 
1. In patients with MUM aged 18 and older, what is the level of anxiety, depression, and 
perceived quality of life? 
2. How many patients with MUM had at least borderline anxiety (scores ≥8), at least 
borderline depression (scores ≥8), and a decrease in global QOL (scores <7)? 
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Hypotheses 
This pilot study was a hypothesis-generating study intended to produce preliminary data 
for a potential larger and powered study that would test the following research hypotheses:  
In patients with MUM: 
1. There is a difference between gender and:  
 anxiety scores 
 depression scores 
 QOL scores 
2. There is a difference between age categories and: 
 anxiety scores 
 depression scores 
 QOL scores 
3. There is a difference between the time elapsed between the initial diagnosis of uveal 
melanoma and the diagnosis of metastasis and: 
 anxiety scores 
 depression scores 
 QOL scores 
4. There is a difference between the duration of illness since metastasis and: 
 anxiety scores 
 depression scores 
 QOL scores 
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Significance 
The chase for the mysteries of uveal melanoma persists. Up until now, research studies 
on uveal melanoma have long focused on the epidemiology of this malignancy, how to halt its 
progression, and how to prolong survival (Eschelman et al., 2013; Field & Harbour, 2014; 
Orloff, Sato, Valsecchi, & Sato, 2015). Dr. Carol Shields, a renowned ophthalmologist and 
ocular oncology specialist has phrased this search as a “continuing hunt for the secrets of uveal 
melanoma” (Shields, 2008). Yet, only a few studies have tackled the psychosocial aspect of 
uveal melanoma from the patient's perspective (Reimer et al., 2006). 
It is undisputable that providing patient-and family-centered care that meets patients’ bio-
psycho-social-spiritual needs improves patients’ satisfaction and sets healthcare organizations 
apart (Institute for Patient- and Family-Centered Care, n.d.). Likewise, healthcare providers who 
are cognizant of their patients’ overall health status hold promise for preserving the quality of 
healthcare for their patients, families, and communities (Institute  on cancer patients and their 
families (McFarland & Holland, 2016). 
The ideology of patient-and family-centered care remains one of the fundamental aims 
for improving the health care quality of patients with MUM. This study is significant in the 
cancer ward because with the rarity of uveal melanoma, and its pattern of disease progression 
and aggressiveness, the quality of a patient's life can be greatly affected by bouts of anxiety, 
depression, and feeling of low perceived emotional support. Our study examined the levels of 
these psychosocial challenges among patients with MUM, which had not been previously 
reviewed. Tackling these serious concerns has the potential to improve quality of life. 
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Literature Review 
Psychosocial Distress in Cancer Patients 
Patients diagnosed with cancer are likely to present symptoms associated with 
psychosocial disturbances, including anxiety, depression, and decreased quality of life (Die, 
2012; Mitchell et al., 2011; Schuermeyer et al., 2016). A meta-analysis of 94 interview-based 
studies of 14078 patients with cancer found depression in 20.7%, depression or adjustment 
disorder in 31.6%, and anxiety or any mood disorder in 38.2% (Mitchell et al., 2011).  
Risk Factors for Psychosocial Stress 
Some types of cancer are linked to greater rates of anxiety and depression than others 
(Schuermeyer et al., 2016). There are specific risk factors that have been identified in cancer in 
general that may help to recognize those at greater risk. Some of these factors include gender, 
age, cancer type, and prognosis.  
Studies have suggested that the level of psychiatric disturbances differ by gender (Kessler 
et al., 1994; McLean, Asnaani, Litz, & Hofmann, 2011). Using 20,013 adults from the 
Collaborative Psychiatric Epidemiology Studies (CPES) data, McLean et al. (2011) showed that 
women are more likely than men to develop anxiety disorders throughout the lifetime with a 
male: female prevalence ratio of 1:1.7.  
Another prospective longitudinal study was conducted among 500 cancer patients with an 
average age of 73.1 to investigate the association between age, anxiety, and depression in older 
adults diagnosed with cancer (Weiss et al., 2015). In this study, clinically significant anxiety was 
reported in 20.9% and clinically significant depression was reported in 12.6% (Weiss et al., 
2015). Additionally, it was noted that with increasing age, anxiety decreased while depression 
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remained constant (Weiss et al., 2015). Hence, it is warranted to assess and address the 
psychological sequelae of cancer across the age spectrum. 
A synthesis of the literature reviewed showed that psychological distress in cancer 
patients depends on the cancer type and varies overtime (Reimer et al., 2006; Schuermeyer et al., 
2016; Turnbull et al., 2012). The dynamic life altering experiences suggests the necessity to 
examine bio-psycho-social-spiritual needs of cancer patients in daily clinical practice in light of 
patient-centered care approach.  
Psychosocial Distress in Patients with Metastatic Uveal Melanoma  
The poor prognosis of uveal melanoma despite advanced treatment multimodalities 
(ACS, 2014; Eschelman, et al., 2013; Singh, Turell, & Topham, 2011) makes it likely for uveal 
melanoma patients to incur psychosocial distress and life-changing challenges that may impact 
the quality of life throughout the continuum of care from the initial diagnosis of uveal melanoma 
to metastasis, survivorship, and end of life.  
Prior studies have already begun to show that the diagnosis of uveal melanoma and its 
progression impair the holistic well-being of individuals and their families beyond the physical 
appearance and the clinical presentation of the patient.  In a prospective study among 54 patients 
diagnosed with uveal melanoma, Reimer and his colleagues (2006) found that the diagnosis of 
choroidal melanoma impaired quality of life, which was further compromised among patients 
who underwent eye radiotherapy. Data were collected before eye radiotherapy and at 3 months 
after radioactive eye therapy. They found that global QOL of ocular melanoma patients 
deteriorated after radioactive therapy likely due to the increase in patients with visual damage 
from 21 preoperatively to 34 postoperatively (Reimer et al., 2006). 
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As noted above, factors influencing psychosocial distress and affect quality of life are 
complex and change throughout the continuum of care. In a prospective longitudinal study of 96 
patients with uveal melanoma at an institutional referral practice, Schuermeyer et al. (2016) 
revealed that patients who underwent prognostication for their primary uveal melanoma had the 
highest level of decision regret at 3 months following prognostic genetic testing. However, this 
decision regret decreased at 12 months following this testing. Nevertheless, little is known 
regarding the variation in the level of psychosocial needs of patients with MUM when metastasis 
occurs and throughout the continuum of care. 
In this study, a more tailored approach to understanding the needs of patients with MUM 
was evaluated taking into consideration the demographic status, the time elapsed between the 
initial diagnosis of uveal melanoma and metastasis, and the duration of illness since the 
diagnosis of metastasis in order to provide more effective psychosocial support. 
Theoretical Foundation 
In examining a theoretical perspective that supports the value of exploring the level of 
anxiety, depression, and quality of life in patients with MUM as well as tailoring a psychosocial 
management plan to match the needs of the particular patient to improve quality of life, the 
psychosocial oncology framework provides a useful model. This theoretical framework 
conceptualizes what type of psychosocial help cancer patients and their families might require 
and proposes service delivery approach at both the provider and system levels (Turnbull et al., 
2012). Basically, this framework echoes the advantage of regularly assessing the needs of people 
affected by cancer, implementing routine supportive care screening, identifying supportive care 
needs, providing referral and linkages to suitable services, and ameliorating the capacity of the 
health system to address and provide comprehensive care (Turnbull et al., 2012). 
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The framework for psychosocial oncology care provides a concrete set of 31 actionable 
recommendations grouped into 8 major domains upon which the cancer care team may 
collectively utilize to review existing services, identify gaps, and revise services to ensure quality 
psychosocial care and services based on psychosocial distress experienced by cancer patients and 
their families (Turnbull et al., 2012). These domains aim to raise awareness and understanding of 
psychosocial care (Domain A), provide standard of care for screening and management of 
psychosocial health care needs (Domain B), delineate expectation of health care providers in 
terms of education, training, and communication of psychosocial issues (Domain C), define 
patient and family education (Domain D), explain quality oversight and monitor progress of 
psychosocial services (Domain E), enlighten workforce competencies for cancer services 
(Domain F), standardize transdisciplinary classification for psychosocial health services (Domain 
G), and promote psychosocial research (Domain H) (Turnbull et al., 2012). 
The principles of psychosocial and supportive care needs have been recommended in the 
care of patients with the diagnosis of cancer (Fitch, 2008; State Government Victoria, n.d.; 
Turnbull et al., 2012; Yun et al., 2010). Similarly, in the care of patients with MUM, it is 
essential to plan care based on what type of needs and services these patients and their families 
might necessitate in the domains of physical, psychological, social, information, and spiritual 
across the cancer trajectory from initial diagnosis of metastatic uveal melanoma through 
bereavement. Henceforth, in light of the interprofessional care approach extended to patients 
with MUM and their families, the principles of supportive care needs may be applied to establish 
and deliver psychosocial care in an attempt to improve the quality of life of these patients.  
ANXIETY-DEPRESSION-QUALITY OF LIFE  12 
Identifying and Defining Variables 
The psychosocial disturbances among metastatic uveal melanoma patients may echo the 
dependent variables of the level of anxiety, level of depression, and the perceived quality of life. 
These dependent variables may be affected by independent clinical variables of the time elapsed 
between the initial diagnosis of uveal melanoma and the diagnosis of metastasis, and the duration 
of illness since the diagnosis of metastasis. In addition, independent demographic variables of 
gender and age range may have an impact on bio-psycho-social-spiritual health of these patients. 
Other demographic variables include race/ethnicity, level of education, employment status, 
marital status, parental status, and being a parent of a child younger than 18 years. 
The variables with theoretical and operational definitions are displayed in Table 1. The 
causal interaction of variables within this study is depicted in Appendix A. 
Methods 
Research Design 
A descriptive-comparative survey design was used in this research study.  This survey, 
collected at one point in time, addressed the proposed research question on the level of anxiety, 
level of depression, and perceived quality of life in patients with MUM aged 18 years and older. 
Also, it addressed the proposed research question on how many patients with MUM had at least 
borderline anxiety (scores ≥8), at least borderline depression (scores ≥8), and a decrease in 
global QOL (scores <7). Moreover, this design was appropriate to explore whether there is a 
difference in level of anxiety, level of depression, and perceived quality of life in patients with 
MUM based on their gender, age categories, the time elapsed between the initial diagnosis of 
uveal melanoma and metastasis, and the duration of illness since metastasis.  
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Study Sample 
 The target population of this study was all patients with MUM receiving care at a Mid-
Atlantic referral practice of MUM. Other inclusion criteria for this pilot study included patients 
with MUM aged 18 years and older, residing in the United States regardless of their gender, race 
or ethnic backgrounds, religion, belief, education, socioeconomic status, or state of residence. As 
of May 15, 2017, there were 136 patients with MUM established in this institution. They were 
comprised of 60 male and 76 female. Based on their age group, 2 were between the age of 18 
and 34 years, 81 were between the age of 35 and 60 years, and 53 were over 60 years. These 
patients were notified in writing about the study.  
Sample Size 
In this convenience sampling, we approached only established patients with MUM who 
presented at this Mid-Atlantic institution for treatment or clinical follow-ups during the three- 
month study period of September 1 - December 1, 2017. Patients who could not read the surveys 
were included and voluntarily completed the survey with the assistance of the investigators who 
read questions to them. Patients who did not speak English were excluded from this study. There 
were 70 eligible patients with MUM who met the above criteria (Appendix B). 
Power Analysis  
This pilot study was intended to provide preliminary data for a potential larger and 
powered study which would examine whether there is a relationship between the endpoints (level 
of anxiety, level of depression, and perceived quality of life) and demographic and socio-
economic variables as well as the time elapsed between the initial diagnosis of uveal melanoma 
and the diagnosis of metastasis and the duration of illness since the diagnosis of metastasis. 
Given the poor prognosis of metastatic uveal melanoma and the limited survival rate (ACS, 
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2014), we expected 30-40% of patients with MUM to have a score of 8 or more on the Hospital 
Anxiety and Depression Scale (HADS) reflecting at least borderline anxiety or depression. If true 
in the population, then a sample of 50 patients would provide 95% Clopper-Pearson exact 
confidence intervals for the estimated prevalence of anxiety of (0.18, 0.45) and (0.26, 0.55), for 
prevalence estimates 30% and 40%, respectively (Appendix B). 
Recruitment of Subjects 
Following two institutional review board (IRB) approvals, the principal investigator 
mailed the IRB approved invitation flyer and subject recruitment letter to all patients with MUM 
receiving care at a Mid-Atlantic referral practice of MUM. Both the flyer and the recruitment 
letter specified the ages for eligibility, stipulated the anonymity of the participants, stated the 
purpose of the study, included the benefits of participation, specified the contact person’s name, 
and identified the location of the study. Thereafter, the investigators met with every patient with 
MUM who presented at the multidisciplinary melanoma clinic, outpatient infusion center, or 
inpatient care area during the allotted study period of 3 months to ensure that the patient had 
received the recruitment letter, answer questions about the study, and determine whether the 
patient wanted to participate.  
Setting 
The setting for this study was a large teaching hospital in the Mid-Atlantic, a referral 
practice of MUM.  
Instruments and Measurement 
The demographic data sheet (Appendix C), the HADS (Appendix D), and the World 
Health Organization Quality of Life (WHOQOL)-BREF questionnaire (Appendix E) were used 
to collect data in this study. The demographic data sheet included questions on the independent 
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variables, namely, gender, age range, the time elapsed between the initial diagnosis of uveal 
melanoma and metastasis, and the duration of illness since the diagnosis of metastasis. Other 
demographic data collected were race, ethnicity, highest level of education completed, 
employment status, marital status, parental status, and being a parent of a child < 18 years. 
Participants were not required to provide their names, date and month of birth, addresses, phone 
numbers, or any other identifiable information on the survey. Permission to use HADS and 
WHOQOL-BREF questionnaire were granted by GL Education Group Limited and World 
Health Organization, respectively. 
During the period of September 1 - December 1, 2017, a one data collection point using 
paper surveys of the HADS (Appendix D) and the WHOQOL-BREF (Appendix E) were 
distributed to patients with MUM who had voluntarily agreed to participate in this study. 
Surveys were completed and collected on the same day at the multidisciplinary melanoma clinic, 
outpatient infusion center, or inpatient care area. The principal investigator or the co-investigator 
was present on site to assist with the completion of the survey as needed. At the end of the 
survey, a handmade thank you gift from Rwanda, the principal investigator’s native country, was 
given to participants (Appendix F). To our knowledge, there was no previous study that has used 
HADS or WHOQOL-BREF in patients with MUM.   
Hospital Anxiety and Depression Scale 
The hospital anxiety and depression scale (HADS) is a frequently used psychological 
screening instrument that has been applied in clinical and research settings. It gives clinically 
meaningful screening of anxiety and depression in both individual patients with illness and in the 
general population (GL Education Group, n.d.). In a review of literature of the validity of the 
HADS, Bjelland, Dahl, Haug, and Neckelmann (2002) have identified 747 articles in Medline, 
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ISI, and PsycINFO that have referred to HADS. HADS encompasses seven questions for anxiety 
and seven questions for depression that can be completed in about 2 to 5 minutes (Stern, 2014; 
Appendix D). It was deemed to be a reliable and valid instrument for screening anxiety and 
depression in individuals (Bjelland et al., 2002; Stern, 2014). Scores for each subscale range 
from 0 to 21 and are 4-point Likert scale with a range of 0-3. The level of anxiety or depression 
score is estimated to be normal (0-7), borderline abnormal (score 8-10), and abnormal (score 11-
21) (Bjelland, Dahl, Haug, & Neckelmann, 2002; Zigmond & Snaith, 1983). A score of 8 or 
more for anxiety has a specificity of 0.78 and a sensitivity of 0.9 whereas the same score for 
depression has a specificity of 0.79 and a sensitivity of 0.83 (Bjelland et al., 2002; Stern, 2014). 
Thus, a score of 8 or more for anxiety or depression should alert the clinician for a thorough 
psychosocial and mental health evaluation. 
World Health Organization Quality of Life-BREF 
The World Health Organization Quality of Life (WHOQOL)-BREF is a 26-item version 
of the WHOQOL-100 assessment (WHO, 2004; Skevington, Lotfy, O'Connell, & WHOQOL 
Group, 2004). It was reported that WHOQOL-BREF could be self-administered in UK by well 
people, in less than 5 min (Skevington et al., 2004). The WHOQOL-BREF consists of seven 
items in the domain of physical health (QOL domain 1) which includes mobility, daily activities, 
functional capacity, energy, pain, and sleep; six items in psychological health (QOL domain 2) 
which is pertinent to self-image, negative thoughts, positive attitudes, self-esteem, mentality, 
learning ability, memory concentration, religion, and the mental status; three items in social 
relationships (QOL domain 3) which is related to personal relationships, social support, and sex 
life; eight items in environmental health (QOL domain 4) which includes issues related to 
financial resources, safety, health and social services, living physical environment, opportunities 
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to acquire new skills and knowledge, recreation, general environment (noise, air pollution, etc.), 
and transportation; as well as two items in global QOL and general health (WHO, 2004; 
Appendix I). Each item is Likert scaled from 1 to 5 on a response scale which correlates to a 
five-point on an ordinal scale. Scores range from 7 to 35 in domain 1, from 6 to 30 in domain 2, 
from 3 to 15 in domain 3, from 8 to 40 in domain 4, and from 2 to 10 in global QOL (Skevington 
et al., 2004; WHO, 2004). A higher score in each domain corresponds to a better QOL (WHO, 
2004).  
The WHOQOL-BREF has been tested in numerous populations worldwide and is 
considered to be a rigorous cross-culturally valid and reliable assessment of QOL (Skevington et 
al., 2004). A large study of 11,830 individuals from 24 countries responded to the WHOQOL-
BREF questionnaire. Among them, 17% had a diagnosis of cancer, 11% had diabetes, 11% had 
depression, 11% had cardiovascular diseases and hypertension, and 4% had musculoskeletal 
problems (Skevington et al., 2004). In this study, a measure of the internal consistency showed 
Cronbach’s alpha of 0.82 for domain 1 of physical health, 0.81 for domain 2 of psychological 
health, 0.68 for domain 3 of social relationships, and 0.80 for domain 4 of environmental health 
(Skevington et al., 2004). To establish discriminant validity, mean scores for facets and domains 
of physical, psychological, level of independence, social relations, environment, and spirit were 
calculated for 4644 ill and 3187 well sample populations (WHO, 1998). The WHOQOL-100 
showed scores ranging from 5% to 18.5% lower for ill participants than for well participants on 
all four domains (WHO, 1998). 
Data Collection Procedure 
 Data collection began following both institutional review board approval. The data 
collection was performed by either the principal investigator or the co-investigator from 
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September 1, 2017 through December 1, 2017. The paper-pencil survey was distributed daily to 
patients with MUM who presented at the Mid-Atlantic referral practice of MUM for their 
treatment or clinic appointment during the survey period. The investigator collected the survey in 
a sealable envelope on the same day immediately after completion. To prevent duplicates in the 
survey, respondents were asked to complete the survey only once. Approximately 15 minutes 
were expected to complete both the HADS and WHOQOL-BREF questionnaires (Skevington et 
al., 2004; Stern, 2014). There was a handmade ornament from Rwanda given to participants after 
taking the survey (Appendix F). The completed surveys were placed in the principal 
investigator’s locked desk. The key for the locked box was kept in the researcher’s office.  
To ensure fidelity to study protocol as well as validity and reliability of data collection 
plan, surveys were organized and available to all patients with MUM based on their clinical 
appointments during the data collection period. This process facilitated in delivering the survey 
as intended and could be replicated to other patients with MUM who receive care in other 
institutions. In addition, all variables were clearly demarcated to facilitate data abstraction 
(Borrelli, 2011). The principal investigator entered all data on a password protected 
Microsoft Excel worksheet (Appendix G). Also, one of this project’s co-advisors checked 10% 
of the sample for accuracy of data entry. Data codes are defined in Appendix H.  
Data Analysis Plan 
In our study, a descriptive analysis was conducted for demographic and clinical 
characteristics of the sample. Also, descriptive statistics were used to analyze data collected, 
including the frequency and percent for categorical data as well as the mean and standard 
deviation for interval data. Once recoded, data from Excel were downloaded directly into IBM 
SPSS Statistics 24 for data storage, analysis, and reporting. With this pilot study, we examined 
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whether there were potential differences in the level of anxiety, level of depression, and QOL in 
patients with MUM based on gender, age categories, and the time elapsed between the initial 
diagnosis of uveal melanoma and metastasis using an independent t-test. Moreover, we tested 
whether there were potential differences in the level of anxiety, level of depression, and QOL in 
patients with MUM based on the duration of illness since the diagnosis of metastasis using 
analysis of variance (ANOVA) and p-value. 
The independent t-test was used to analyze two averages means on the same dependent 
variable (Statistics How To, 2017). ANOVA was used to analyze the variation in a scale-level 
dependent variable having more than 2 categories (Statistics Solutions, 2013). The p-value was 
calculated to illustrate the probability of observing the data if the null hypothesis was true and 
helped support or reject the null hypothesis (Statistics How To, 2017).  Cronbach’s Alpha was 
used to measure the reliability of dependent variables. 
By assuming that there was a difference in level of anxiety, level of depression, and QOL 
in patients with MUM based on gender, the independent t-test was used to assess if the 
dependent variables of anxiety score, depression score, and QOL scores were related to the 
independent variable of gender (2 groups). By positing that there was a difference in level of 
anxiety, level of depression, and QOL in patients with MUM based on two age categories of 18 
years to ≤60 years and above 60 years, the independent t-test was used to assess if the dependent 
variables of anxiety score, depression score, and QOL scores were related to the independent 
variable of age groups (2 groups). By assuming that there was a difference in level of anxiety, 
level of depression, and QOL in patients with MUM based on the time elapsed between the 
initial diagnosis of uveal melanoma and the diagnosis of metastasis, the independent t-test was 
used to evaluate if the dependent variables of anxiety score, depression score, and QOL scores 
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were related to the independent variable of time elapsed between the initial diagnosis of uveal 
melanoma and the diagnosis of metastasis (2 groups). By postulating that there was a difference 
in level of anxiety, level of depression, and QOL in patients with MUM based on the duration of 
illness since the diagnosis of metastasis, ANOVA was used to evaluate if the dependent variables 
of anxiety score, depression score, and QOL scores were related to the independent variable of 
duration of illness since the diagnosis of metastasis (3 groups).  
In addition, we conjectured that there was a difference among each domain of quality of 
life (physical health, psychological health, social relationships, and environmental health) based 
on gender, age range, time elapsed between the initial diagnosis of uveal melanoma and 
metastasis, and duration of illness since the diagnosis of metastasis. In the same way, the 
independent t-test was used to assess if each domain of QOL and the global health were related 
to the independent variable of gender, age categories, and the time elapsed between the initial 
diagnosis of uveal melanoma and the diagnosis of metastasis. ANOVA was used to evaluate if 
each domain of QOL was related to the independent variable of the duration of illness since the 
diagnosis of metastasis (3 groups). 
Steps for checking and cleaning data and computing domain scores for the WHOQOL-
BREF are delineated in Appendix I. 
Ethical Considerations 
This oncology-related study on patients with MUM was approved by the Melanoma 
Multidisciplinary Disease Group (MDG), approved by the Protocol Facilitation Committee, 
approved by the Protocol Review Committee (PRC), acknowledged by the Office of Nursing 
Research, and exempted by the IRB. Study participation was voluntary. The data collection 
spreadsheet was password protected.   
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Results 
Reliability testing 
In this study, a measure of the internal reliability of the hospital anxiety and depression 
scale showed Cronbach’s alpha of 0.81 for anxiety and Cronbach’s alpha of 0.83 for depression. 
A measure of the internal reliability of the World Health Organization Quality of Life-BREF 
questionnaire showed Cronbach’s alpha of 0.84 for domain 1 of physical health, 0.89 for domain 
2 of psychological health, 0.90 for domain 4 of environmental health, and 0.56 for global QOL. 
It also showed very low internal consistency between the 3 items in domain 3 of social 
relationships (Cronbach’s alpha of 0.004) due to item 21 asking “How satisfied are you with 
your sex life?” If this item was deleted, Cronbach’s Alpha would have been 0.68 for domain 3. 
Demographic and Clinical Characteristic of the Sample 
There were 136 potentially eligible patients with MUM. Only 70 patients with MUM 
presented to the Mid-Atlantic referral practice of MUM during the allotted survey period of 
September 1-December 1, 2017 and were offered to complete the survey. Among them, 65 
completed the survey with a response rate of 93%.  Of the total sample, the majority were female 
(56.9 %, n=37), older than 60 years (55.4%, n=36), white (98.5%, n=64), had a college education 
or above (78.5%, n=51), non-employed (56.9%, n=37), married (80%, n=52), parents of children 
(83.1%, n=54), but did not have a child less than 18 years (73.8%, n=48; Table 2).  
The time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of 
metastasis was <1 year in 10.8% (n=7), 1 year to <5 years in 61.5% (n=40), <5 years in 72.3% 
(n=47), and ≥ 5 years in 27.7% (n=18). The duration of illness since the diagnosis of metastasis 
was <1 year in 29.2% (n=19), 1 year to <5 years in 55.4% (n=36), and ≥ 5 years in 15.4% 
(n=10).  
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Research Questions Results 
In our total sample, (Table 3), the mean anxiety score was 6.05 ± 3.64, the mean 
depression score was 3.48 ± 3.27, the mean domain 1 score for physical health was 27.28 ± 5.38, 
the mean domain 2 score for psychological health was 23.52 ± 4.59, the mean domain 3 score for 
social relationships was 11.71 ± 2.35, the mean domain 4 score for environmental health was 
34.40 ± 5.13, and the mean score for global QOL was 7.22 ± 1.57. In addition, among 
respondents with MUM, 30.8% (n=20) had anxiety scores ≥8, 13.8% (n=9) had depression 
scores ≥ 8, and 32.3% (n=21) had global QOL scores <7 (Table 2) indicating at least borderline 
anxiety, at least borderline depression, and decreased QOL scores. 
Hypotheses Testing Results 
Hypothesis 1, which was tested to calculate differences in anxiety, depression, and QOL 
scores by gender, found no significant difference in any of the scores (Table 4).  
Hypothesis 2 was tested to look for differences in anxiety, depression, and QOL scores 
by age groups (Table 5). Participants aged 18 to ≤60 years had significantly higher anxiety 
scores (7.52 ± 3.65) than participants > 60 years (4.86 ± 3.21; p=0.003; Table 5). Participants 
aged 18 to ≤60 years had significantly lower QOL domain 4 scores of environmental health 
(32.48 ± 5.23) than participants > 60 years (35.94 ± 4.55; p=0.006; Table 5). No significant 
differences were found in depression scores, QOL domain 1, QOL domain 2, QOL domain 3, or 
global QOL scores based on age groups (Table 5). 
Hypothesis 3 was tested to determine differences in anxiety, depression, and QOL scores 
by the time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of 
metastasis (Table 6). No significant differences were found in anxiety scores, depression scores, 
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the four QOL domains, or in the global QOL based on the time elapsed between the initial 
diagnosis of uveal melanoma and the diagnosis of metastasis (Table 6).  
Hypothesis 4, which was tested to look for differences in anxiety, depression, and QOL 
scores by the duration of illness since the diagnosis of metastasis (Table 7), revealed significant 
difference in anxiety scores among the three groups (p=0.01; Table 7). Our results showed that 
group variances were homogenous. LSD Post hoc analysis revealed that anxiety scores were 
significantly higher in the < 1 year group (7.79 ± 3.72) compared to the 1 year to <5 years group 
(5.75 ± 3.45; p=0.04), and were significantly higher in the < 1 year group (7.79 ± 3.72) 
compared to the ≥ 5 years group (3.80 ± 2.78; p=0.004). There were no statistical significance in 
anxiety scores between the 1 year to <5 years group and the ≥ 5 years group (p=0.12). 
Moreover, our results showed difference in QOL domain 1 scores for physical health 
among the three groups (p=0.05; Table 7). The Least Significant Difference (LSD) Post hoc 
analysis revealed that QOL domain 1 scores were significantly higher in the < 1 year group 
(29.11 ± 4.03) compared to the 1 year to <5 years group (25.81 ± 5.85; p=0.03). There were no 
statistical significance in QOL domain 1 scores between the < 1 year group and the ≥ 5 years 
group (p=0.99) or between the 1 year to <5 years group and the ≥ 5 years group (p=0.08). No 
significant differences were found in depression scores, QOL domain 2, QOL domain 3, QOL 
domain 4, or global QOL based on the duration of illness since metastasis (Table 7). 
Discussion 
As a referral practice for patients with MUM, we were in a unique position to assess the 
levels of anxiety, depression, and quality of life among patients with MUM aged 18 years and 
older and determine how many of them had at least borderline anxiety (scores ≥8), at least 
borderline depression (scores ≥8), and a decrease in global QOL (scores <7). In our sample there 
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were unequal demographic distribution of gender (more female), age range (more older than 60 
years), race (more White), ethnicity (more not Hispanic or Latino), highest level of education 
completed (more with college education or above), employment status (more non-employed), 
marital status (more married), parental status (more parents of children), and being a parent of a 
child < 18 years (more without a child less than 18 years). Also, there were unequal distribution 
of clinical characteristics of the time elapsed between the initial diagnosis of uveal melanoma 
and metastasis (more with 1 year to <5 years), and the duration of illness since metastasis (more 
with 1 year to <5 years). This unequal distribution may have influenced results although it likely 
reflected the actual demographic and clinical characteristics of patients with MUM.  
Moreover, we asked participants to identify themselves in one of the following 3 age 
groups: 18-34 year group, 35-60 year group, and >60 year group (Appendix C). We had only 2 
patients in the 18-34 year group so we combined the 18-34 year group and the 35-60 year group 
into the 18-60 year group. It is possible that the results would have been different if the age 
groups were broken down based on the four adult generations identified by the Pew Research 
Center (2015): Millennials, (ages 20 to 35 in 2016), Generation X (ages 36 to 51 in 2016), 
Boomers (ages 52 to 70 in 2016), and the Silent generation (ages 71 to 88 in 2016). 
Similar to previous studies assessing psychosocial disturbances in patients diagnosed 
with cancer (Die, 2012; Mitchell et al., 2011; Schuermeyer et al., 2016), approximately one third 
of participants had clinically significant anxiety and decreased global QOL. This supports the 
concept that the diagnosis of MUM impairs the holistic well-being of patients beyond their 
physical examination and clinical presentation.   
Also, we hypothesized that there would be a difference in anxiety, depression, and QOL 
scores in patients with MUM by gender. Our results showed that gender was not a differentiating 
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factor for anxiety scores, depression scores, global QOL scores, or the four QOL domain scores. 
These results are different than those of other studies which have indicated that females had 
higher anxiety and psychiatric disturbances than males (Kessler et al., 1994; McLean et al., 
2011). However, it may be that the sample size in our study did not yield sufficient power to 
completely address these endpoints. 
Moreover, we hypothesized that there would be a difference in anxiety, depression, and 
QOL scores in patients with MUM by age groups. Our results showed that participants aged 18 
to ≤60 years had significantly higher anxiety scores than participants > 60 years. This is in 
parallel with Weiss et al. (2015) study which noted that anxiety decreased with increasing age. 
Also, participants aged 18 to ≤60 years had significantly lower QOL domain 3 scores of social 
relationships than participants > 60 years. The increased anxiety and impaired social 
relationships among younger patients with MUM may be due to the diagnosis of MUM 
potentiated by the socio-economics constraints that face people aged 18 to ≤60 years such as 
financial, marriage, and career-oriented pressures. Likewise, in examining how quality of life in 
Ireland varied by age group and social class, using central statistics office data available for 
2013, the Economic and Social Research Institute (2016) found that the rate of multiple quality 
of life problems was 1.8 times higher in younger adults than in older adults. No significant 
differences were found in depression scores, QOL domain 1, QOL domain 2, QOL domain 3, 
and global QOL based on age groups.  Albeit statistically insignificant differences in these QOL 
domains and global QOL scores between age cohorts, the mean scores were higher in 
participants > 60 years.   
Furthermore, we hypothesized that there would be a difference in anxiety, depression, 
and QOL scores in patients with MUM by the time elapsed between the initial diagnosis of uveal 
ANXIETY-DEPRESSION-QUALITY OF LIFE  26 
melanoma and the diagnosis of metastasis. Our results showed no significant differences in 
anxiety scores, depression scores, the four QOL domains, and in the global QOL based on the 
time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of metastasis. 
This may be, that for the most part, patients diagnosed with MUM do not exhibit debilitating 
symptoms after the initial treatment of uveal melanoma. Chabert, Velikay-Parel & Zehetmayer 
(2004) noted that patients with uveal cancer appeared relatively well and displayed fewer signs 
of decline. However, it may be that the unequally sized groups by the time elapsed between the 
initial diagnosis of uveal melanoma and the diagnosis of metastasis in our study did not yield 
enough power to completely address these endpoints.  
In addition, we hypothesized that there would be a difference in anxiety, depression, and 
QOL scores by the duration of illness since the diagnosis of metastasis. Participants with < 1 
year since the diagnosis of metastasis had significantly higher anxiety scores and higher QOL 
domain 1 scores for physical health. No significant differences were found in depression scores, 
QOL domain 2, QOL domain 3, QOL domain 4, and in the global QOL based on the duration of 
illness since metastasis. The level of anxiety is increased among patients with MUM with < 1 
year since the diagnosis of metastasis but the QOL of their physical health is not markedly 
affected. During the first year of the diagnosis of metastasis, these patients are in good physical 
health yet going through a disturbing experience.  
Overall, up to 30% of participants had at least borderline anxiety and a decreased global 
QOL while up to 10% had at least borderline depression. These findings have never been 
identified in this population although they are clinically significant to justify the need and 
importance for integrating psycho-social practices in the care of patients with MUM. 
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Study Limitations 
The first limitation of this study was the sample size. Generalization of the findings may 
be limited as the participants in our study were all part of one institution located in the Mid-
Atlantic region. The results of the level of anxiety, depression, and QOL may be unique to 
patients with MUM of this institution. Another limitation was that the sample size of each 
category by gender, age groups, was not equally distributed, which could influence the results 
and conclusion.  In addition, the research may have produced different results if other variables 
were also measured such as financial strain, the distance and mode of transport from residence to 
the institution, and other forms of deprivation.  
Implications and Recommendations for Practice, Policy, and Research 
The results of our current study have implications in clinical practice algorithms of 
patients with MUM as they reveal a significant level of anxiety, level of depression, and 
decreased QOL among these patients. The psychosocial oncology framework by Turnbull et al. 
(2012) can be used to present our findings to the multidisciplinary oncology team and have the 
team discuss and collectively develop processes to raise awareness among clinicians and patients 
about the findings. The team is encouraged to reflect on the current assessment and determine 
how the findings can influence a new standard of care regarding a biopsychosocial assessment of 
patients with MUM and a development of a plan that links patients and caregivers with necessary 
psychosocial services. 
The first step will be for healthcare providers to correctly identify patients who are 
experiencing anxiety, depression, and decreased quality of life.  While patients aged 18-60 have 
a higher overall anxiety score, both age ranges remain at risk and should be screened.  Gender 
and time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of metastasis 
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are not differentiating factors for anxiety scores, depression scores, global QOL scores, or the 
four QOL domain scores. Time since diagnosis of metastatic malignancy however is associated 
and thus our plan will initially be rolled out to identify patients who are within 1 year of their 
diagnosis of MUM.   To identify these patients more reliably, we will target their first 
hospitalization for liver-directed therapy. We recommend training healthcare providers on how 
to utilize the HADS and WHOQOL-BREF questionnaire and document anxiety score, 
depression score, and QOL scores upon this encounter and then quarterly. 
Based on the assessment and diagnosis, the second step will be for the clinician to set and 
document measurable and achievable short- and long-term goals specific to every patient with 
MUM that might include getting out of the house for a walk at least thirty minutes per day, 
eating small but frequent nutritious meals, managing pain and nausea through adequate 
medications, consulting a psychiatrist/social worker/case management, recommending music 
relaxation, and referring to relaxation techniques for health (American Nurses Association 
[ANA], 2018; National Center for Complementary and Integrative Health, 2017). 
The third step will be for the clinician to follow the care plan established through the 
continuum of care during hospitalization and outpatient (ANA, 2018). Patient identified to have 
increased physiological needs and/or socio-psychological distress should be called 2 to 3 days 
after hospital discharge by a member of the clinical staff preferably who was on the discharge 
team. Throughout the continuum of care, the patient’s status and the effectiveness of the care 
plan must be evaluated and modified as needed putting forward holistic and patient-focused care 
in an attempt to improve the quality of life of these patients (ANA, 2018). 
Further research should address anxiety, depression, and QOL with a larger population 
sample of patients diagnosed with MUM, and possibly extend research to other patients 
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diagnosed with other types of cancer. Also, we recommend a study looking at the Millennials 
(ages 22 to 37 in 2018), Generation X (ages 38 to 53 in 2018), Boomers (ages 54 to 72 in 2018), 
and the Silent generation (ages 73 to 90 in 2018). A comparison between strategies used in 
different institutions to address anxiety, depression, and QOL may assist clinicians to learn from 
each other in order to improve the QOL of patients with MUM through the continuum of care.  
Conclusions 
In an attempt to improve the quality of life of patients with metastatic uveal melanoma, it 
is essential to examine bio-psycho-social-spiritual needs of these patients in daily clinical 
practice. The findings of this study offer important contributions by showing the significant level 
of anxiety, level of depression, and decreased QOL in patients with MUM using the HADS and 
the WHOQOL-BREF questionnaire. It also explored differences by gender, age range, time 
elapsed between the initial diagnosis of uveal melanoma and metastasis, and duration of illness 
since metastasis. Participants aged 18 to ≤60 years had significantly higher anxiety scores and 
lower QOL domain 4 scores of environmental health. Participants with < 1 year since the 
diagnosis of metastasis had significantly higher anxiety scores and higher QOL domain 1 scores 
for physical health. Gender and time elapsed between the initial diagnosis of uveal melanoma 
and metastasis were not differentiating factors for anxiety scores, depression scores, global QOL 
scores, or the four QOL domain scores. 
The findings of our study also guide stakeholders involved in the care of patients with 
MUM to integrate a translational strategic plan addressing bio-psycho-social-spiritual needs in 
light of patient-centered care approach to improve the quality of life of these patients. The 
psychosocial oncology framework by Turnbull et al. (2012) provided a useful model for this 
study. 
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Table 1. Variables Affecting Psychosocial Health of Patients with MUM  
Variable Theoretical Definition Operational Definition 
Dependent Variable   
Level of anxiety (interval) 
 
Degree of fear, nervousness, 
uneasiness, and nerve-
racking as measured by 
scores on the HADS 
Actual anxiety score 0-21  
 
 
Level of depression (interval) Degree of ongoing feeling 
of sadness and loss of 
interest as measured by 
scores on the HADS 
Actual depression score 0-21  
 
 
Quality of life (interval) General well-being of 
individuals in terms of 
health and happiness as 
measured by scores on the 
WHOQOL-BREF. 
 
There is no total score of 
WHOQOL-BREF. Scores 
are reported by domains and 
the two global questions are 
reported separately. Lower 
score scores denote lower 
QOL while higher scores 
denote higher QOL. 
1. Domaine 1 = Physical 
health: (6-Q3) + (6-Q4) + 
Q10 + Q15 + Q16 + Q17 + 
Q18 (Raw score 7-35)  
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Variable Theoretical Definition Operational Definition 
2. Domaine 2 = 
Psychological health: Q5 + 
Q6 + Q7 + Q11 + Q19 + (6-
Q26) (Raw score 6-30) 
3. Domaine 3 = Social 
relationships: Q20 + Q21 + 
Q22 (Raw score 3-15) 
4. Domaine 4 = 
Environmental health: Q8 + 
Q9 + Q12 + Q13 + Q14 + 
Q23 + Q24 + Q25 (Raw 
score 8-40) 
5. Global QOL/General 
health: Q1 + Q2 (Raw score 
2-10) 
 Independent Variable 
 
  
Age range (nominal) Category of years a person 
has lived  
1. Age 18 to  ≤60 years  
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Variable Theoretical Definition Operational Definition 
The time elapsed between the 
initial diagnosis of uveal 
melanoma and the diagnosis 
of metastasis (Categorical) 
 
Years/months lapsed from 
the diagnosis of uveal 
melanoma to the diagnosis 
of metastasis 
1. <5 years 
2. ≥ 5 years 
The duration of illness since 
the diagnosis of metastasis 
(Categorical) 
 
Years/months elapsed since 
diagnosed with MUM as 
reported by patient 
1. <1 year 
2. 1 year to <5 years 
3. ≥ 5 years 
Demographic Variable  
 
  
Race (nominal) Biological and physical 
characteristics shared by a 
group of individuals as 
identified by patient 
Race: 
1. Black or African 
American 
2. White 
3. Prefer Not to Disclose 
Ethnicity (nominal) Cultural traits shared by a 
group of individuals as 
identified by patient 
Ethnicity: 
1. Hispanic or Latino 
2. Not Hispanic or Latino 
3. Other 
Marital status (nominal)  
 
Current relationship 1. Married 
2. Non-Married 
Parental status (Nominal) Identification of whether or 
not a person is a parent 
 
0= Parent without a child 
1= Parent with a child 
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Variable Theoretical Definition Operational Definition 
Being a parent of a child < 18 
years (Nominal) 
Personal identifying of 
being a parent of a child 
younger than 18 years 
Age group of child 
0. No child (<18 years) 
1. Child (0- <18 years) 
Level of education 
(Categorical) 
Highest level of schooling 
completed 
1= High School or less  




Status of current 
employment 
1= Employed 
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 65 (100) 20 (30.8) 9 (13.8) 21 (32.3) 
Gender     
       Male 28 (43.1) 7 (10.8) 1 (1.5) 7 (10.8) 
     Female 37 (56.9) 12 (18.5) 8 (12.3) 14 (21.5) 
Age groups     
   18 to ≤60 years 29 (44.6) 13 (20) 4 (6.2) 12 (18.5) 
    >60 years 36 (55.4)   7 (10.8) 5 (7.7)    9 (13.8) 
Race*     
   White 64 (98.5) 20 (30.8) 9 (13.8) 21 (32.3) 
   African 
American 
  1 (1.5)    
Ethnicity     
   Hispanic or 
Latino 
  2 (3.1)    
   Not Hispanic 
or Latino 
50 (76.9) 16 (24.6) 7 (10.8) 18 (27.7) 
   Other 11 (16.9)   4 (6.2) 1 (1.5)   3 (4.6) 
Education     
    High school or 
less 
14 (21.5)   4 (6.2) 4 (6.2)   3 (4.6) 
    College or 
above 
51 (78.5) 16 (24.6) 5 (7.7) 18 (27.7) 
Employment 
status 
    
   Employed   28 (43.1) 12 (18.5) 6 (9.2) 11 (16.9) 












   Non-Employed 37 (56.9)   8 (12.3) 3 (4.6) 10 (15.4) 
Marital status     
    Married 52 (80) 14 (21.5) 5 (7.7) 16 (24.6) 
    Non- married 13 (20)   6 (9.2) 4 (6.2)   5 (7.7) 
Parental status     
    No children   8 (12.3)   2 (3.1) 1 (1.5)   2 (3.1) 
   Yes children 54 (83.1) 16 (24.6) 7 (10.8) 17 (26.1) 
Being a parent of 
a child <18 years 
    
    No child (< 18 
years) 
48 (73.8) 12 (18.5) 7 (10.8) 13 (20) 
   Child (0- < 18 
years) 
  8 (12.3)   4 (6.2) 1 (1.5)   4 (6.2) 





the diagnosis of 
metastasis 
    
      <1 year 7 (10.8)   2 (3.1) 1 (1.5)   2 (3.1) 
     1 year to <5 
years 
40 (61.5) 13 (20) 5 (7.7) 14 (21.5) 
        <5 years 47 (72.3) 15 (23.1) 6 (9.2) 16 (24.6) 
        ≥ 5 years 18 (27.7)   5 (7.7) 3 (4.6)   5 (7.7) 
The duration of 
illness since the 
diagnosis of 
metastasis 
    












      <1 year 19 (29.2) 9 (13.8) 3 (4.6)   6 (9.2) 
1 year to <5 
years 
36 (55.4) 9 (13.8) 5 (7.7) 12 (18.5) 
      ≥ 5 years 10 (15) 1 (1.5) 1 (1.5)   3 (4.6) 
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Anxiety (score) 6.05 (3.64) 0 16 
Depression (score) 3.48  (3.27) 0 13 
QOL Domain 1 27.28 (5.38) 15 35 
QOL Domain 2 23.52 (4.59) 11 30 
QOL Domain 3 11.71 (2.35) 5 15 
QOL Domain 4 34.40 (5.13) 22 40 
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Table 4. Differences in Anxiety, Depression, and QOL Scores by Gender 








Anxiety (score)   5.68 (3.62)   6.32 (3.68) -0.71 0.48 
Depression (score)   2.71 (2.39)   4.05 (3.73) -1.76 0.84 
QOL Domain 1 27.89 (4.98) 26.81 (5.68) 0.80 0.43 
QOL Domain 2 24.46 (4.36) 22.81 (4.70) 1.45 0.15 
QOL Domain 3 12.07 (2.16) 11.43 (2.48) 1.09 0.28 
QOL Domain 4 34.14 (4.56) 34.59 (5.57) -0.35 0.73 
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Table 5. Differences in Anxiety, Depression, and QOL Scores by Age Group 
 Age range in years Analysis P value 
Age 18 to ≤60 years 
n=29, 44.6% 
Mean (SD) 




Anxiety (score)   7.52 (3.65)   4.86 (3.21) 3.12 0.003 
Depression (score)   3.52  (3.31)   3.44 (3.28) 0.09 0.93 
QOL Domain 1 26.31 (5.55) 28.06 (5.18) -1.31 0.20 
QOL Domain 2 22.83 (5.16) 24.08 (4.07) -1.10 0.28 
QOL Domain 3 11.21 (2.88) 12.11 (1.75) -1.48 0.15 
QOL Domain 4 32.48 (5.23) 35.94 (4.55) -2.85 0.006 
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Table 6. Differences in Anxiety, Depression, and QOL Scores by the Time Elapsed between 
Initial Diagnosis of Uveal Melanoma and Metastasis  
 Time elapsed between 
initial diagnosis of uveal 
melanoma and 
metastasis  
< 5 years 
n=47, 72.3% 
Mean (SD) 
Time elapsed between 
initial diagnosis of uveal 
melanoma and 
metastasis  







Anxiety (score)   6.45 (3.74)   5.00 (3.22) 1.45 0.15 
Depression (score)   3.91 (3.35)   2.33 (2.83) 1.77 0.08 
QOL Domain 1 27.34 (5.35) 27.11 (5.58) 0.15 0.88 
QOL Domain 2 23.04 (4.46) 24.78 (4.83) -1.37 0.18 
QOL Domain 3 11.57 (2.50) 12.06 (1.92) -0.74 0.47 
QOL Domain 4 33.94 (5.19) 35.61 (4.89) -1.18 0.24 
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Table 7. Differences in Anxiety, Depression, and QOL Scores by the Duration of Illness since 
Metastasis  
 Duration of 
illness since 
metastasis  


















Anxiety (score)    7.79 (3.72)   5.75 (3.45)   3.80 (2.78) 4.88 0.01 
Depression (score)    3.05 (2.97)   4.08 (3.43)   2.10 (2.96) 1.70 0.19 
QOL Domain 1 29.11 (4.03) 25.81 (5.85) 29.10 (4.56) 3.23 0.05 
QOL Domain 2 23.68 (4.76) 22.72 (4.60) 26.10 (3.51) 2.23 0.12 
QOL Domain 3 12.11 (2.69) 11.19 (2.19) 12.80 (1.87) 2.18 0.11 
QOL Domain 4 34.42 (5.17) 33.56 (5.33) 37.40 (3.20) 2.22 0.12 
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Appendix A 
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Appendix B 










ANXIETY-DEPRESSION-QUALITY OF LIFE  50 
Appendix C 
Biographical Data and Personal Timeline of the Diagnosis of Metastatic Uveal Melanoma 
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Appendix D 
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Appendix F 
Handmade Ornament from Rwanda 
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Appendix H 




ANXIETY-DEPRESSION-QUALITY OF LIFE  62 
 Appendix I 
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